sorafenib has been researched along with Leukemia, Pre-B-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beitzen-Heineke, A; Fiedler, W; Reinert, J; Schwartz, S; Stelljes, M; Wethmar, K | 1 |
| Chen, W; Collins, R; Tirado, CA; Wakim, JJ | 1 |
1 review(s) available for sorafenib and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature.
Topics: Antineoplastic Agents; Benzenesulfonates; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Diagnosis, Differential; Humans; Myeloproliferative Disorders; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcr; Pyridines; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic | 2011 |
1 other study(ies) available for sorafenib and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
Loss of CD22 expression and expansion of a CD22
Topics: Adult; Aged, 80 and over; Allografts; Antibodies, Bispecific; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clone Cells; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Inotuzumab Ozogamicin; Lymphocyte Subsets; Male; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Sorafenib; Treatment Failure; Young Adult | 2021 |